- 2023 Multidisciplinary Oncology Review
- 2022
- Videos
- 2021
- 2020
- 2019
- Hematology & Medical Oncology Review 2019
- 2018
- Events
Playback speed
10 seconds
TP53 Mutations in MDS: Is Combination of Eprenetapopt + AZA Well-Tolerated in Patients With TP53-Mutant MDS & Oligoblastic AML? What Are the Rates of Clinical Response & Molecular Remissions?
0 views
March 5, 2021
Comments 0
Login to view comments.
Click here to Login
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases